Compare KFRC & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KFRC | PRTC |
|---|---|---|
| Founded | 1962 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 499.7M | 464.3M |
| IPO Year | 1996 | N/A |
| Metric | KFRC | PRTC |
|---|---|---|
| Price | $26.15 | $16.26 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $38.50 | N/A |
| AVG Volume (30 Days) | ★ 271.6K | 3.9K |
| Earning Date | 04-27-2026 | 04-29-2026 |
| Dividend Yield | ★ 6.19% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.96 | N/A |
| Revenue | ★ $1,329,007,000.00 | N/A |
| Revenue This Year | $2.78 | N/A |
| Revenue Next Year | $4.32 | N/A |
| P/E Ratio | $13.21 | ★ $8.09 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $24.49 | $13.30 |
| 52 Week High | $50.14 | $20.00 |
| Indicator | KFRC | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 37.98 | 39.90 |
| Support Level | $25.01 | $15.72 |
| Resistance Level | $28.41 | $18.10 |
| Average True Range (ATR) | 1.13 | 0.54 |
| MACD | 0.16 | -0.08 |
| Stochastic Oscillator | 30.15 | 8.42 |
Kforce Inc is a solutions firm specializing in technology, finance, accounting, and other professional staffing services. The company operates two business segments: the Technology segment, which provides talent solutions with candidates skilled in areas including systems/applications architecture and development, data management and analytics, business and artificial intelligence, machine learning, project and program management, and network architecture and security. The FA segment offers consultants in traditional finance and accounting roles such as finance, planning and analysis; business intelligence analysis; general accounting; transactional accounting, business and cost analysis; and taxation and treasury. The majority of revenue is earned through the Technology segment.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.